BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23913164)

  • 1. TDP1 and PARP1 deficiency are cytotoxic to rhabdomyosarcoma cells.
    Fam HK; Walton C; Mitra SA; Chowdhury M; Osborne N; Choi K; Sun G; Wong PC; O'Sullivan MJ; Turashvili G; Aparicio S; Triche TJ; Bond M; Pallen CJ; Boerkoel CF
    Mol Cancer Res; 2013 Oct; 11(10):1179-92. PubMed ID: 23913164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage.
    Das BB; Huang SY; Murai J; Rehman I; Amé JC; Sengupta S; Das SK; Majumdar P; Zhang H; Biard D; Majumder HK; Schreiber V; Pommier Y
    Nucleic Acids Res; 2014 Apr; 42(7):4435-49. PubMed ID: 24493735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based assays.
    Dean RA; Fam HK; An J; Choi K; Shimizu Y; Jones SJ; Boerkoel CF; Interthal H; Pfeifer TA
    J Biomol Screen; 2014 Dec; 19(10):1372-82. PubMed ID: 25117203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(ADP-ribose)polymerase 1 stimulates the AP-site cleavage activity of tyrosyl-DNA phosphodiesterase 1.
    Lebedeva NA; Anarbaev RO; Sukhanova M; Vasil'eva IA; Rechkunova NI; Lavrik OI
    Biosci Rep; 2015 Jun; 35(4):. PubMed ID: 26181362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy.
    Alagoz M; Wells OS; El-Khamisy SF
    Nucleic Acids Res; 2014 Mar; 42(5):3089-103. PubMed ID: 24335147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.
    Al Abo M; Sasanuma H; Liu X; Rajapakse VN; Huang SY; Kiselev E; Takeda S; Plunkett W; Pommier Y
    Mol Cancer Ther; 2017 Nov; 16(11):2543-2551. PubMed ID: 28802254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.
    Perego P; Cossa G; Tinelli S; Corna E; Carenini N; Gatti L; De Cesare M; Ciusani E; Zunino F; Luison E; Canevari S; Zaffaroni N; Beretta GL
    Biochem Pharmacol; 2012 Jan; 83(1):27-36. PubMed ID: 21978643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Hybrid Compounds Combining Fragments of Usnic Acid and Thioether Are Inhibitors of Human Enzymes TDP1, TDP2 and PARP1.
    Dyrkheeva NS; Filimonov AS; Luzina OA; Orlova KA; Chernyshova IA; Kornienko TE; Malakhova AA; Medvedev SP; Zakharenko AL; Ilina ES; Anarbaev RO; Naumenko KN; Klabenkova KV; Burakova EA; Stetsenko DA; Zakian SM; Salakhutdinov NF; Lavrik OI
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
    Dedes KJ; Wilkerson PM; Wetterskog D; Weigelt B; Ashworth A; Reis-Filho JS
    Cell Cycle; 2011 Apr; 10(8):1192-9. PubMed ID: 21487248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
    Węsierska-Gądek J; Zulehner N; Ferk F; Składanowski A; Komina O; Maurer M
    Biochem Pharmacol; 2012 Nov; 84(10):1318-31. PubMed ID: 22906755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic Analysis of CRISPR/Cas9-Mediated PARP1-Knockout Cells under the Influence of Topotecan and TDP1 Inhibitor.
    Dyrkheeva NS; Malakhova AA; Zakharenko AL; Okorokova LS; Shtokalo DN; Pavlova SV; Medvedev SP; Zakian SM; Nushtaeva AA; Tupikin AE; Kabilov MR; Khodyreva SN; Luzina OA; Salakhutdinov NF; Lavrik OI
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosyl-DNA phosphodiesterase 2 (TDP2) repairs topoisomerase 1 DNA-protein crosslinks and 3'-blocking lesions in the absence of tyrosyl-DNA phosphodiesterase 1 (TDP1).
    Tsuda M; Kitamasu K; Kumagai C; Sugiyama K; Nakano T; Ide H
    DNA Repair (Amst); 2020; 91-92():102849. PubMed ID: 32460231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
    Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
    Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
    D'Onofrio G; Tramontano F; Dorio AS; Muzi A; Maselli V; Fulgione D; Graziani G; Malanga M; Quesada P
    Biochem Pharmacol; 2011 Jan; 81(2):194-202. PubMed ID: 20875401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform.
    Murai J; Marchand C; Shahane SA; Sun H; Huang R; Zhang Y; Chergui A; Ji J; Doroshow JH; Jadhav A; Takeda S; Xia M; Pommier Y
    DNA Repair (Amst); 2014 Sep; 21():177-82. PubMed ID: 24794403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
    Patel AG; Flatten KS; Schneider PA; Dai NT; McDonald JS; Poirier GG; Kaufmann SH
    J Biol Chem; 2012 Feb; 287(6):4198-210. PubMed ID: 22158865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets.
    Alagoz M; Gilbert DC; El-Khamisy S; Chalmers AJ
    Curr Med Chem; 2012; 19(23):3874-85. PubMed ID: 22788763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage.
    Nitiss KC; Malik M; He X; White SW; Nitiss JL
    Proc Natl Acad Sci U S A; 2006 Jun; 103(24):8953-8. PubMed ID: 16751265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
    Golla RM; Li M; Shen Y; Ji M; Yan Y; Fu K; Greiner TC; McKeithan TW; Chan WC
    Hematol Oncol; 2012 Dec; 30(4):175-9. PubMed ID: 22170260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.